Overreaction or Opportunity? BMO Lowers Novo Nordisk Price Target After Data Release
Impact of CagriSema’s Phase 3 Data Readout on Novo Nordisk BMO Capital Lowers Price Target on Novo Nordisk BMO Capital recently announced that it has lowered the price target on Novo Nordisk (NVO) from $156 to $105. Despite this decrease, the firm maintains an Outperform rating on the shares. The reason for this decision stems…